A couple of hit pieces out after ASCO conference.
Post# of 68
(Total Views: 517)
Posted On: 06/04/2018 10:55:20 AM
A couple of hit pieces out after ASCO conference. Most concern the small sample group and lack of a control group. Yet BMS and Nektar are proceeding into a Phase III trial.
This is a good article on the preliminary results coming out of ASCO 2018.
https://www.forbes.com/sites/matthewherper/20...86c24445b6
I wouldn't try to catch the falling knife today. Let the stock settle and then make your bet.
This is a good article on the preliminary results coming out of ASCO 2018.
https://www.forbes.com/sites/matthewherper/20...86c24445b6
I wouldn't try to catch the falling knife today. Let the stock settle and then make your bet.
(0)
(0)Nektar Therapeutics (NKTR) Stock Research Links
Scroll down for more posts ▼